Abstract: The present disclosure relates to a liquid-cooling radiating pipe and a vacuum interrupter with a built-in liquid-cooling radiating pipe, belonging to the field of vacuum circuit breakers. Based on an original structure of an vacuum interrupter, a liquid-cooling radiating pipe of a Tesla valve structure is arranged in a conductive rod of the vacuum interrupter with the built-in liquid-cooling radiating pipe, and liquid metal is used as a circulating coolant in the liquid-cooling radiating pipe, and by using the self-circulating flow of the liquid metal in the pipeline, the capacity of the conductive rod to dissipate heat to the outside is significantly increased, and the problem of excessive internal temperature rise of a vacuum circuit breaker is effectively solved.

Abstract: A method and non-transitory storage computer-readable medium for performing a neural operator on one or more wellbore measurements. The method may comprise o obtaining one or more measurements, performing a measurement normalization on the one or more measurements to form one or more normalized measurements, forming a material function with the one or more normalized measurements, and forming a neural operator generated physical response with a neural operator and the material function. The method may further comprise forming a beamforming map with the one or more measurements, and forming a neural operator leak source location map with a neural operator and the one or more measurements.

Abstract: A detection method of polyethylene glycol monomethyl ether residue in medicinal materials is provided, which belongs to a technical field of medicinal chemical component detection, and includes: detecting a residual amount of mPEG-2000 in 3000-3400 small-molecule mPEG-b-PDLLA by high-performance liquid chromatography with an evaporative light scattering detector. The present invention solves a problem that the copolymer polyethylene glycol monomethyl ether mPEG and the product polyethylene glycol monomethyl ether-polylactic acid block copolymer mPEG-b-PDLLA are difficult to be separated in the high-performance liquid chromatography and there is no UV absorption. The present invention also has high resolution, high sensitivity, sufficient reproducibility and sufficient selectivity.

Abstract: Described herein are systems and techniques for monitoring for monitoring and evaluating conditions associated with a wellbore and wellbore operations that use neural operators instead of computationally intensive iterative differential equations. Such systems and techniques allow for determinations to be made as operations associated with a wellbore are performed. Instead of having to wait for computationally intensive tasks to be performed or take risks of proceeding with a wellbore operation without real-time evaluations being performed, these wellbore operations may be continued while determinations are timely made, thus improving operation of computing systems that perform evaluations and that make decisions regarding safely and efficiently performing wellbore operations such as drilling a wellbore, cementing wellbore casings in place, or injecting fluids into formations of the Earth.

Abstract: Provided is a multimedia data stream processing method, an electronic device and a storage medium, relating to the field of artificial intelligence, and specifically, to the technical fields of cloud computing, media cloud technology, and the like, which may be applied to scenes such as smart cloud. The multimedia data stream processing method includes: allocating a plurality of sub-streams of a multimedia data stream to a plurality of edge resource nodes, where the multimedia data stream is segmented into a plurality of slices and each of the plurality of sub-streams includes a part of the plurality of slices of the multimedia data stream; and scheduling the plurality of edge resource nodes to provide the plurality of sub-streams of the multimedia data stream for a terminal device.

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

Abstract: A detection method of polyethylene glycol monomethyl ether residue in medicinal materials is provided, which belongs to a technical field of medicinal chemical component detection, and includes: detecting a residual amount of mPEG-2000 in 3000-3400 small-molecule mPEG-b-PDLLA by high-performance liquid chromatography with an evaporative light scattering detector. The present invention solves a problem that the copolymer polyethylene glycol monomethyl ether mPEG and the product polyethylene glycol monomethyl ether-polylactic acid block copolymer mPEG-b-PDLLA are difficult to be separated in the high-performance liquid chromatography and there is no UV absorption. The present invention also has high resolution, high sensitivity, sufficient reproducibility and sufficient selectivity.

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

Abstract: A method of modeling includes quantifying a co-operative strength value for a plurality of pairs of variables, and identifying a clique of at least three variables based on a graph of the co-operative strength values of a plurality of pairs of variables. The method also includes selecting a first pair of variables of the plurality of pairs of variables having a high co-operative strength value. A second clique may also be identified. A model of the first clique and a model of the second clique are made. The outputs of these models are combined to form a combined model which is used to make various decisions with respect to real time data.

Abstract: A method of modeling includes quantifying a co-operative strength value for a plurality of pairs of variables, and identifying a clique of at least three variables based on a graph of the co-operative strength values of a plurality of pairs of variables. The method also includes selecting a first pair of variables of the plurality of pairs of variables having a high co-operative strength value. A second clique may also be identified. A model of the first clique and a model of the second clique are made. The outputs of these models are combined to form a combined model which is used to make various decisions with respect to real time data.